FDA Removes Black Box Warnings on Hormone Replacement Therapy

Historic Regulatory Shift Transforms Women's Healthcare

After more than two decades of fear-based warnings, the U.S. Food and Drug Administration (FDA) is initiating the removal of broad "black box" warnings from HRT products for menopause . The November 2025 decision where the US Department of Health and Human Services and the FDA announced the removal of the black box warnings, which went into effect in February 2026 , represents a seismic shift in how medical professionals and patients approach menopause treatment.

FDA Commissioner Marty Makary and other agency officials said the warnings are based on outdated science and have discouraged women from taking hormone therapy . The original warnings stemmed from a Women's Health Initiative study that found a statistically non-significant increase in the risk of breast cancer diagnosis. The average age of women in the study was 63 years — over a decade past the average age of a woman experiencing menopause — and study participants were given a hormone formulation no longer in common use .

"Tragically, tens of millions of women have been denied the life-changing and long-term health benefits of hormone replacement therapy because of a medical dogma rooted in a distortion of risk," said FDA Commissioner Makary . The regulatory change affects approximately 41 million women in the United States aged 45 to 64 years, approximately 2 million received a hormone therapy prescription in 2020.

Timing and Benefits Drive New Evidence-Based Approach

The updated guidance emphasizes what researchers call the "timing hypothesis." Women who initiate HRT within 10 years of the onset of menopause (generally before age 60) have a reduction in all-cause mortality and fractures. Women may also reduce their risk of cardiovascular diseases by as much as 50%, Alzheimer's disease by 35%, and bone fractures by 50 to 60% .

If you start menopause hormone therapy before age 60 or within 10 years of menopause, the benefits may outweigh the risks . For most women, experts agree that HT helps to control moderate to severe menopause symptoms such as hot flashes when initiated within 10 years of onset of menopause or under age 60 years .

The therapy addresses multiple health concerns beyond symptom relief. Systemic estrogen therapy (with or without progestin) has been shown to be the best treatment for hot flashes and night sweats. Systemic estrogen protects against the bone loss that occurs early in menopause. This can help prevent osteoporosis . Research also shows women who use HT have a lower risk of developing type 2 diabetes .

Personalized Medicine Takes Center Stage

"It's a shared decision-making process with your doctor," says Cedars-Sinai Fertility and Reproductive Medicine Center reproductive endocrinologist Dr. Jessica Chan . The new approach recognizes that Your healthcare provider can help determine if the benefits of HRT outweigh the risks , considering individual factors including age, medical history, and family health patterns.

Treatment options have expanded significantly. Systemic estrogen comes as a pill, skin patch, ring, gel, cream or spray. Systemic estrogen is absorbed by the whole body and can be used to treat many common symptoms of menopause . Transdermal estrogen patches, for example, carry a lower risk of stroke and blood clots than oral estrogen .

Risk considerations remain important but are now viewed in proper context. They also carry risks, such as blood clots and breast cancer. The breast cancer risk usually doesn't rise until after about 5 years with estrogen plus progestogen therapy (EPT) or after 7 years with estrogen alone .

A New Era for Women's Health

The regulatory change reflects broader momentum in women's healthcare advocacy. "With today's action, we are delivering on our promise to make sure women have accurate, scientifically grounded information about the potentially life-changing benefits of HRT," said FDA Commissioner Marty Makary, M.D., M.P.H. "Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions."

The transformation extends beyond regulatory language to clinical practice. "The attitude toward hormone therapy has changed in recent years. Most medical societies support not only the 'lowest dose for the shortest time' but also 'the appropriate dose for the appropriate amount of time.'" This shift acknowledges that menopause treatment should be individualized rather than constrained by blanket restrictions.

As healthcare providers and patients navigate this new landscape, the emphasis on evidence-based medicine promises to restore confidence in treatments that can significantly improve quality of life during a natural but often challenging life transition.